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Abstract:  Hemoglobinopathies  are  a  group  of  inherited  hemoglobin  disorders.  Initially 
described in the subtropical regions, they are now spread all around the world because of 
migration.  Their  high  frequency  and  clinical  severity  make  them  a  major  public  health 
problem  mostly in  Africa  due  to  the  limited  resources  reserved  for  the  management  and 
prevention of these diseases. Despite considerable advances in the control and management of 
the hemoglobinopathies, therapeutic approach and follow- up still pose problems because of 
the major economic and organizational difficulties in the developing countries , particularly in 
Africa  where  problems  are  majored  by  other  factors  including  social  and  cultural 
backgrounds, high consanguinity, as well as the coexistence of infection and malnutrition.
Effective  prevention  programs  have  been  carried  out  successfully  in  many  European 
countries concerned by  hemoglobinopathies  . They  should be extended to African regions 
where hemoglobin disorders account for more than 70% of total hemoglobinopathies in the 
world. Prevention should remain the major priority of  health services to reduce incidence of 
hemoglobinopathies in Africa. Hereby we present the Tunisian experience that may reflect 
globally the profile of the prevention evolution of hemoglobinopathies in North Africa.
Introduction: Hemoglobinopathies are a group 
of  inherited  autosomal  recessive  hemoglobin 
disorders, resulting in the homozygous state, in 
chronic  severe  anemias.  Thalassemias  and 
sickle  cell  diseases  constitute  the  most 
monogenic  hemoglobin  disorders  worldwide. 
Initially  described  in  the  tropical  and 
subtropical regions, they are now common all 
around the world because of migration. 
A  global  epidemiological  database  for 
hemoglobin disorders has been established and 
published  recently  by  the  World  Health 
Organization  (WHO).  Data  collected  in  229 
countries,  clearly  indicated  that 
hemoglobinopathies  constitute  a  significant 
health problem in 71% of those countries which 
include 89% of all births worldwide1.
The  prevalence  of  carriers  of  abnormal 
hemoglobin is within the range of 5-7% in the 
world and the number of new cases of affected 
infants is estimated at 300 000 per year. Among 
them  60 000,  are  born  with  beta-thalassemia 
major  annually,  the  remaining  (83%)  with 
Sickle Cell Disease (SCD).Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Table 1: Demographic data and estimated prevalence of carriers of Hemoglobin disorders and affected conceptions
1
Hemoglobinopathies  in  Africa:  More  than 
70% of total hemoglobin disorders are localized 
in  Africa.  African  population  represents  less 
than 10% of the world population but has the 
highest crude birth  rate  (39.0‰) as shown in 
table 1
1 and also the highest  rate  of  affected
conceptions  (10.78‰)  compared  to  the  one 
registered in the world (2.73‰). 
Among  these  affected  conceptions,  sickle 
cell  diseases  (SCD)  are  largely  prevalent 
(10.68‰)  by  comparison  to  thalassemia 
syndromes  (0.07‰).  In  addition,  it  is  also  in 
Africa  where  we  registered  the  highest 
percentage of under-5 mortality among affected 
births. Table 2
1 shows some practical service 
indicators  highlighting  the  needs  of  care  and 
prevention  for  hemoglobin  (Hb)  disorders  in 
African  sub-regions.  Although  only  17.8% 
from the total births are born in Africa, more 
than 70% of the annual hemoglobin disorders 
are also born in Africa. Most of them concerned 
SCD (85%) and beta-thalassemia major (3.5%). 
In fact the last percentage corresponds to more 
than  1500  beta-thalassemia  patients  born 
annually; this constitutes a heavy burden with 
regards  to  the  high  cost  of  treatment  of 
thalassemia and the low income in the majority 
of African countries.
The  most  concerned  regions  by  beta-
thalassemia  in  Africa  are  the  western  Africa 
and  the Northern  Africa  with  respectively 
63.88% and 22.17% of the total annual affected 
conceptions.  The  major  forms  of  alpha 
thalassemia are almost absent in Africa.
Table  2: Indicators  of  annual  service  needs  for  hemoglobin 
disorders
1
REGION Annual affected conceptions
Sickle cell 
disorders  beta thal alpha thal
Total 
annual 
disorders
African 
Region  233 289 1 520 11 234 819
Northern 
Africa 181 337 0 627
Western 
Africa  167 224 971 0 9 622
Middle 
Africa  40 688 27 0 4 184
Eastern 
Africa  25 184 183 11 6 974
Southern 
Africa  11 2 0 1 487
World 276 168 42 409 13 466 332 043
In  North  Africa:  North  Africa  consists  of  5 
countries:  Mauritania,  Morocco,  Algeria, 
Tunisia  and  Libya  (Figure  1)  with  a  total 
population of 87 millions of inhabitants and a 
birth rate ranging between 16.8‰ and 40.9‰. 
The  geographical  position  of  this  area  at  the 
parting  of  the  ways  between  sub-Saharan 
African countries and the Mediterranean makes
Population  Demography
2003 % of the population carrying Affected conceptions 
(per 1000)
  % of under-
5 mortality  
In Affected 
births
Populatio
n 
(millions)
Crude birth 
rate
(‰)
Annual 
births 
(1000s)
Under-5 
mortality 
rate (‰)
Sig-nificant  
Hb variant 
alpha+ 
thalassaemia
Any 
variant
Sickle cell 
disorders Thalassaemias Total
African 
population 586 39.0 22895 168 18.2 41.2 44.4 10.68 0.07 10.74 6.4
World 
population 6217 20.7 128814 81 5.2 20.7 24.0 2.28 0.46 2.73 3.4Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Figure 1: Geographical situation of North African countries
North  Africa  well  concerned  by 
hemoglobinopathies. The inherited hemoglobin 
disorders  are  frequently  encountered  in  this 
population and present a great diversity in the 
phenotypic expression and genetic aspects. 
Many factors may explain, at least partly, 
this  diversity.  The  most  significant  factors 
include  the  historical  context  :  North  Africa 
witnessed several successive waves of invaders 
coming from different origins who settled in the 
region for more or less long periods leading to a 
large  variety  of  genetic  disorders  .Ancient 
social customs, like the high consanguinity rate 
and endogamy,  characterize  those populations 
since  centuries,  and  constitute  an  additional 
factor for dissemination of hemoglobinopathies 
in this area.
Follow-up conditions. Therapeutic approach in 
hemoglobin  disorders,  in  particular  beta-
thalassemia, is based on blood transfusion, iron 
chelation  and  specific  medical  care.  Patients 
present almost the same preoccupations related 
to  growth, schooling,  professional  integration, 
social support and financial cares. 
Because  of  the  high  cost  of  treatment, 
difficulties  in  follow-up  affect  considerably 
patients in North Africa due to low-income of 
concerned  population.  For  these  reasons, 
prevention  of  hemoglobinopathies  becomes  a 
necessity  and  should  be  a  priority  of  basic 
health services to reduce its incidence in each 
country.
Requirements  for  prevention.  The  prevention 
program  must  take  into  account  the 
epidemiological  and  molecular  data  of  each 
concerned  country  to  set  up  the  adequate 
strategy that includes usually: Sensitization and 
information  about  the  disease,  Population 
screening and genetic counselling for carriers, 
and prenatal diagnosis for couples with affected 
children 
Hemoglobinopathies  in  Tunisia:  We  report 
here our experience in Tunisia, as an example 
of a developing country well situated in North 
Africa.  Tunisia  occupies  the  most  northerly 
point of the African continent and covers about 
167.000 square km, projecting northward into 
the Mediterranean Sea,  toward Sicily only 86 
miles  away.  It  lies  approximately  midway 
between  the  straits  of  Gibraltar  and  the  SuezMedit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Figure 2: Carrier prevalence of Hb disorders in the different regions of Tunisia
Canal. This strategic position in North Africa, 
makes  Tunisia  serving  a  cross  road  between 
Europe and Africa and between the Eastern and 
Western parts of the Arab world. 
Berbers were the earliest known inhabitants 
of the area and racially Tunisia’s population is 
in the majority, descendants of the union of the 
Berbers and a large variety of people as Greek, 
Roman,  Vandal,  Byzantines,  Arab,  Spanish, 
and Turkish who have  come to Tunisia  since 
the  Phoenicians,  first  settled  in  the  country  3 
000 years ago. Before it got its independence in Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
1956,  Tunisia  was  a  French  protectorate 
throughout 75 years.
As  a  result  of  this  mixture  of  races  and 
civilizations,  there  is  no  doubt  that  each  of 
these peoples brought a genetic flow, and had a 
great influence on the genetic structure of the 
Tunisians,  leading  to  a  high  frequency  of 
genetic  blood  disorders,  especially  the 
hemoglobinopathies  which  represent  the  most 
common  recessive  inherited  disorder  in 
Mediterranean population.A recent census gave 
demographic data of Tunisia as follows
2: Total 
population  =  9932.4  (x10
3);  Annual  natality 
rate  =  16.8  ‰  ;  Estimated  births  per  year  = 
166834.32; Consanguineous marriages = 33%
Epidemiological   data and distribution of main 
hemoglobinopathies.  The  presence  of  the 
hemoglobinoapathies  in  Tunisia  has  been 
reported as early as 1950
3. Since then, several 
surveys  were  established  to  determine  the 
frequency of these affections in the country. 
The first results  we  reported on that  field 
were  conducted  on  Tunisian  school  children, 
pregnant  women  and  cord  blood  samples, 
noting  that  beta-thalassemia  is  the  most 
frequently  encountered  hemoglobin-pathies 
among  Tunisians
4.  Then  through  a  national 
screening conducted in the military recruitment 
centers,  findings  indicated  that  the  overall 
frequency  of  carriers  in  Tunisia  is  4.48% 
reaching  a  higher  prevalence  in  the  North 
Western  (10.42%)  and  in  the  South  Western 
(5.78%)  parts  of  the  country.  In  addition, 
further  investigations  allowed  to  estimate 
carriers’ prevalence in different regions of the 
country (Figure 2). 
Geographical  distribution  allowed  to 
identify  the  most  affected  areas  which  are 
mainly the cities of Tunis, Béja, Jendouba, Le 
kef, Bizerte, Gafsa, Tozeur, Kasserine, Sousse 
as well as in  the cities of Zaghouan, Nabeul, 
Sidi  Bouzid,  Seliana,  Kairouan,  Sfax  and 
Kebili. 
This  observation  is  of  a  great  interest  to 
guide further research and prevention programs.
Beta-thalassemia  is  the  predominant 
hemoglobin  abnormality  (2.21%)  closely 
followed by the HbS trait (1.89%) (Figure 3).
Finally, the frequency of alpha-thalassemic 
genes, deduced from the presence of Hb Bart’s 
in 2628 cord blood samples, has been estimated 
to 5.48%.
4
The  registered  patients  are  actually  over 
2400 and the number of at risk couples around 
2100 families. The majority of patients (89%) 
are formed by beta-thalassemic patients, sickle 
cell patients(SS)  and  HbS/beta-thalassemia 
patients (Table 3).
Figure 3: carrier frequency of abnormal haemoglobin 
The number of SS patients is unexpectedly 
much higher than beta-thalassemic patients that 
would  be  probably  related  to  the  greater 
tolerance of sickle cell anemia in this country 
and  the  natural  selection  of  beta-thalassemia 
major who, more severely affected, die in early 
age of life. 
Furthermore,  according  to  patient  origin, 
geographical  distribution  demonstrated  once 
again  the  higher  concentration  of  beta-
thalassemia in the North Western as mentioned 
above with a newly discovered focus region at 
Kasserine in the central west of Tunisia where 
we  observed  the  highest  number  of  beta-
thalassemic  patients:  27.36%  of  the  total 
number registered through the country (Table 
4).We also note that the most at risk region for 
sickle  cell  is  the  North  Western  Tunisia 
(59.70%). 
Molecular  basis  of  beta-thalassemia. 
Identification of beta-thalassemia mutations  is 
also  a  pre-requisite  for  prevention  programs 
before  undertaking  the  prenatal  diagnosis 
offered to at risk couples.The spectrum of beta-Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Table 3: Registered patients (1980-2006)
thalassemia  mutations  in  the  Tunisian 
population (Table 5) revealed a great molecular 
heterogeneity  with  actually  28  different  beta 
thalassemia alleles (6); two common alleles, the 
codon  39  (CT)  non  sens  mutation  and  the 
beta
+ IVS1-110 (AG) mutation accounted for 
70%  of  total  beta-thalassemia  mutations 
detected in Tunisia; this undoubtedly facilitates 
the  choice  of  the  adapted  strategy  in  the 
practice of prenatal diagnosis.
Table 4:  Distribution  of the  main  major  hemoglobinopathies. 
Figure  legend:  GT-global  territory,  NE-north  east,  NW-north 
west,  CE-central  east,  CW-central  west,  SE-south  east,  SW-
south west.
-thalassemia 
major 
Sickle cell disease
Nb % Nb %
GT 37 4.99 130 8.52
NE 129 17.39 297 19.46
NW 268 36.12 911 59.70
CE 71 9.57 45 2.95
SE 9 1.21 13 0.85
CW 203 27.36 37 2.42
SW 25 3.37 93 6.09
Total 742 100.00 1526 100.00
Prevention  program.  Epidemiological  and 
molecular  data  mentioned  above  are 
fundamental  to  approach  prevention  program. 
They allow in particular to identify the most at 
risk regions and the particular spectrum of beta-
thalassemia  mutations  among  Tunisians  and 
also  the  correlations  between  phenotype  and 
genotype  which  may  have  an  important 
influence  in  the  orientation  of  genetic 
counselling. 
Prenatal  diagnosis.  The  first  setting  up  of 
prenatal  diagnosis  started  in  1991  after  a 
transfer of technology based on PCR methods
The  System  was  fully  functional  at  the 
beginning  of  1994. Demands  of  Prenatal
diagnosis  (PND)  followed  a  relatively  good 
evolution  indicating  a  progressive  increase  in
Table 5: Spectrum of -thal mutations among Tunisians (Total 
chromosomes  studied = 470)
Mutation  Type Frequenc
y
cd39  (C-->T) ° 49.0%
IVS1-110 (G-->A) + 21.0%
IVS1-1(G-->A) ° 4.5%
cd44 (-C) ° 3.8%
IVS 1-2(T-->G) ° 3.0%
cd30 (G-->C)  3.2%
IVS 2- 745 (C-->G) ° 2.6%
cd6(-A) ° 2.6%
IVS1-5 (G-->A)  1.5%
-87  (C-->G)  1.7%
IVS1-5 (G-->C)  1.0%
-30 (T-->A)  0.8%
cd25/26 (+T) ° 0.6%
IVS 1-6  (T-->C)  0.6%
IVS2-1(G-->A) ° 0.6%
cd5 (-CT) ° 0.4%
IVS 2-848  (C-->A)  0.4%
IVS2-849  (A-->C)  0.4%
cd8 (-AA) ° 0.2%
cd47 (+A) ° 0.2%
cd106/107 (+G) ° 0.2%
uniditified 1.9%
Total 100%
Nb of 
Patients
Nb of 
CAR
b thal maj 742 637
SS patients 925 830
S/b-thal 480 420
CC 35 35
OO 5 6
SC 76 68
SOArab 43 37
C/b-thal 34 27
O/b-thal 23 19
HbH 14 11
other (SD, CO,etc….) 17 16
Total 2394 2106Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
. 
Table 6 : NeoNatal Screening of Hemoglobinopathies
the number of at risk couples who desire PND. 
(Figure 4) Between 1997 and 2006 a total of 
268 PND were performed revealing 79 affected 
fetus  (29.5%).  Termination  pregnancy  was 
accepted in 96.5% of cases; refusal was only in 
3  cases (3.8%):  for  religious  reason  (1  case), 
delayed diagnosis (2 cases). According to our 
experience,  acceptability  of  PND  depends  on 
genetic information including the pertinence of 
genetic counselling and the comprehension by 
families.  In  addition,  usually  at  risk  couples 
decide  more  easily  for  abortion  option  when 
fetus  is  affected  by  beta-thalassemia  major 
because of the severity of the disease compared 
to SS fetus or another SCD. This is also true 
when existence of an affected proband in  the 
family.
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Figure 4: Prenatal diagnosis (PND) among at risk Tunisian
couples (1995-2006)
Despite  a  large  information  and 
sensitization campaign on hemoglobinopathies, 
many pregnant women from at risk families do 
not present or present too late, (after the third 
trimester  of  gestation)  for  prenatal  test,  thus 
they lose the prenatal diagnosis benefit.
Neonatal screening. Neonatal screening started 
in Tunisia as a pilot study in two maternities in 
the city of Tunis and aimed at detecting sickle 
cell disease and beta
0 thalassemia at early age 
in order to reduce the under-5 mortality rate in 
the  affected  infants.  Our  experience  was 
successful (Table 6) allowing to take in charge 
precocely  the  affected  babies  and  to  identify 
numerous  at  risk  couples  to  be  counseled 
during  their  eventual  next  pregnancies;  this 
pilot program has been extended recently to a 
high risk region in the North Western Tunisia.
Premarital screening. Premarital screening was 
carried out randomly on 53 couples; 18% were 
detected  at  risk  suggesting  the  importance  of 
this  test  to  secure  at  risk  couples  against 
affected  progenitor. The  screening  program 
needs to be supported by public awareness and 
regular education in concerned populations.
Discussion:  Hemoglobinopathies  constitute  a 
real public Health problem in the large majority 
of  African  countries  and  contribute,  at  least 
partly, in the increasing rate of infant mortality 
and morbidity. In the only North Africa Region, 
demographic and epidemiologic data allow to 
estimate  the  number  of  new  cases  of  babies 
who  are  born  with  a  severe  form  of 
hemoglobinoathie at as much as 419 every year 
in  Tunisia,  Algeria  and  Morocco  and  around
2000/year if we include Mauritania and Libya 
where carrier rates of abnormal hemoglobin are
Pilot study Results
Samples studied
(19 months)
Minor Forms Major Forms
AS other min forms Thal maj
Sickle cell 
syndromes
Total maj 
forms
Nb 13000 260 351 6 5 14
Abnormal Hb Ratio 1/50 1/37 1/2166 1/2600 1/928
From total live birthsMedit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Table 7: Carrier frequencies of abnormal hemoglobin in North African Countries
Country Global 
frequency %
% Carrier
References
-thal HbS HbC Other (HbO Arab,
HbD, ..)
Algeria 3.50 1-60-2.0 0.70 0.40 - [ 7 ] , [ 8 ]
Libya 14.13 7.77 4.51 - 1.85 [ 9 ] 
Mauritania 16.60 2.53 8.71 3.00 2.36 [ 10 ] 
Marocco 2.61 0.95 0.59 1.07 - [ 11 ] 
Tunisia 4.48 2.21 1.89 0.23 0.15 [ 5 ] 
much higher (Table 7)
5,7,8,9,10,11.
We can easily imagine the heavy burden of 
this  large  number  of  patients  on  health  care 
resources, knowing that the direct cost of the 
management  for  one  patient  is  estimated  to 
about 7000DT/year (5000 US $).
In reality the whole problem still lies in the 
difficulties  in  the  diagnosis  of  abnormal 
hemoglobin  traits  and  in  the  very  limited 
economic resources that do not permit to take in 
charge correctly the numerous patients already 
identified. Several affected children die before 
reaching the 10
th year of life. Still this figure is 
probably understated because of the existence 
of local concentration of the disease and of the 
high degree of consanguinity, reaching a rate of 
70%  in  some  rural  areas.  In  addition, 
heterozygote  detection  should  be  conducted 
carefully  in  these  countries  where  iron 
deficiency is a major problem for the diagnosis 
of heterozygous beta-thalassemia since it may 
mask  an  elevation  of  HbA2 level.  Our 
experience  in  Tunisia  demonstrates  that 
premarital  screening  is  the  best  option  and 
should be mandatory in any prevention program 
for  hemoglobinopathies.  Thus  most  at  risk 
couples  are  identified  early  for  prenatal 
diagnosis  in  the  first  pregnancy  and  would 
regularly  produce  healthy  offspring. 
Unfortunately many at risk couples yet discover  
their  risk  only  after  the  birth  of  their  first 
affected  child.  In  Tunisia,  neonatal  screening 
was  decided  to  reach  the  maximum  of 
concerned  families;  its  efficiency  is  more 
evident in population of at risk regions. Success 
will depend on a good coordination and a good 
cooperation between parents and medical staff.
Moreover,  in  the  most  African  countries, 
data  on  epidemiology  of  hemoglobinopathies 
are  scarce,  and  insufficiently  precise  to 
undertake  a  solid  program  of  control  and 
prevention for these genetic diseases. The few 
preventive  actions  conducted  in  this  context 
remain uncompleted and need to be developed 
efficiently by opting to the best adapted way, 
economical and cost-effective.
To improve the situation, public education 
about thalassemia and sickle cell diseases is of 
a  great  importance  and  should  be  carried  out 
through periodic meetings addressed to health 
professionals  including  doctors  and  nurses 
working  in  the  community,  and  family 
members. Also,  all means  of mass media  are 
helpful  as  well  as  the  sensitization  through 
patient  parents’associations  that  facilitates  the 
contact  with  families  and  the  diffusion  of 
information  through  didactic  supports 
(brochures, booklets ect…).  
Conclusions:  Sickle  cell  diseases,  -
thalassemia and other hemoglobinopathies are 
frequent  in  Africa.  Their  distribution  varies 
from  one  region  to  another.  Western  and 
Northern  Africa  are  the  most  affected  areas. 
Their clinical severity and the poor conditions 
of  medical  care  make  hemoglobinopathies  a 
real public health problem in each country. 
Prevention  program  at  national  level, 
remains  the  best  alternative  to  control Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
hemoglobinopathies  in  most  concerned 
countries. It should include:
(1)  An  active  sensitization  of  population, 
notably among the youth; 
(2) Integration  of  hemoglobin  study  as  a 
mandatory pre-marital test;
(3) Providing  freely  genetic  counselling  to 
carriers  and  at  risk  couples  for 
hemoglobinopathies; 
(4) Extend  the  neonatal  screening  of 
hemoglobinopathies to all at risk regions;
(5)  Maintain  updated  the  national  patients 
register  for  hemoglobinopathies  in  the 
country  for  prospective  prevention 
actions.
Taking in account that SCD present 83% of 
total haemoglobin diseases, a recent resolution 
from UN recognizes SCD as a priority of public 
health and declares the 19
th of June of each year 
as  international  day  to  fight  against  these 
affections. 
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